GlassScriptPhysician profile
Steven G Johnson
NPI 1265439038
$11,216.86
in general payments reported to CMS, 2019-2025
35 companies · $2,508 in 2025
The $2,508 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $735 · 2021: $1,315 · 2022: $1,728 · 2023: $1,476 · 2024: $2,397 · 2025: $2,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,292 · Education: $89.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,291.54 |
| Education | $89.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,545.14 | 2019-2025 | |
| Janssen Biotech, INC. | $1,580.12 | 2019-2025 | Tremfya, Stelara, Remicade |
| Gilead Sciences, INC. | $843.28 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $666.35 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $596.14 | 2019-2025 | Entyvio |
| Celltrion USA INC. | $550.20 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Intercept Pharmaceuticals, INC. | $446.41 | 2019-2024 | Ocaliva |
| Redhill Biopharma INC. | $414.93 | 2020-2023 | Aemcolo, Talicia, Movantik |
| Celgene Corporation | $293.61 | 2021-2024 | Zeposia |
| Pfizer INC. | $271.35 | 2023-2025 | |
| Madrigal Pharmaceuticals | $221.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Vivus LLC | $196.21 | 2024-2025 | Pancreaze |
| Nestle Healthcare Nutrition INC. | $178.01 | 2021-2023 | |
| Lilly USA, LLC | $170.08 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $156.10 | 2021-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $138.96 | 2019-2023 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $127.04 | 2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $125.01 | 2023 | |
| Braintree Laboratories, INC. | $116.74 | 2022-2025 | Sutab, Suflave |
| Ipsen Biopharmaceuticals, INC | $90.59 | 2025 | Iqirvo |
| Boston Scientific Corporation | $75.85 | 2019-2025 | Watchman Flx |
| Ardelyx, INC. | $72.54 | 2023-2025 | Ibsrela |
| Shionogi INC | $71.97 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $43.46 | 2024 | |
| Daiichi Sankyo INC. | $42.73 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $32.20 | 2023 | Andexxa |
| Phathom Pharmaceuticals, INC. | $25.03 | 2024 | Voquezna |
| Caris Mpi, INC. | $22.65 | 2025 | Mi Cancer Seek |
| Allergan, INC. | $20.59 | 2020 | |
| Ferring Pharmaceuticals INC. | $19.67 | 2023 | Rebyota |
| Echosens North America, INC. | $15.50 | 2020 | |
| Novo Nordisk INC | $14.02 | 2025 | Wegovy |
| Axonics, INC. | $12.55 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $11.91 | 2023 | Lockado |
| Acacia Pharma INC | $8.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.